NEWSROOM

MEDIA CONTACTS

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Galderma launches Dysport® in China for treatment of glabellar lines

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year

Galderma Receives FDA Approval For Restylane® Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth

Galderma closes the sale of Bübchen to Dallmann’s Pharma

CETAPHIL by Galderma unites forces to focus on hand health and safety with their "In Good Hands" initiative to fight COVID-19

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

What are you looking for?

Galderma Global

NEWSROOM

MEDIA CONTACTS

Filter news by date

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Galderma launches Dysport® in China for treatment of glabellar lines

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year

Galderma Receives FDA Approval For Restylane® Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth

Galderma closes the sale of Bübchen to Dallmann’s Pharma

CETAPHIL by Galderma unites forces to focus on hand health and safety with their "In Good Hands" initiative to fight COVID-19

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

NEWSROOM

MEDIA CONTACTS

Filter news by date

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Galderma launches Dysport® in China for treatment of glabellar lines

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

Galderma global research reveals struggles of people with rosacea and psoriasis of the face experiencing a lack of control and impact on mental wellbeing

Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport® (abobotulinumtoxinA) Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Year

Galderma Receives FDA Approval For Restylane® Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth

Galderma closes the sale of Bübchen to Dallmann’s Pharma

CETAPHIL by Galderma unites forces to focus on hand health and safety with their "In Good Hands" initiative to fight COVID-19

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*

Galderma Announces New England Journal of Medicine Publication from Phase 2 Study of Investigational Therapy Nemolizumab in Patients with Moderate to Severe Prurigo Nodularis

Confirm navigation